Abeona Therapeutics Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Abeona Therapeutics Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Growth Efficiency Ratio: Sales grew 312% in 3 years; of every extra $100 of sales, $2,517 became extra profit. Higher than 98% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-15.8×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 56% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 1/3Sales grew in 2 of the last 3 years; profit grew in 1 of 3.
Less steady than 51% of Healthcare companies in United States.
Growth Efficiency Ratio
$2,517Sales grew 312% in 3 years; of every extra $100 of sales, $2,517 became extra profit.
Higher than 98% of Healthcare companies in United States.
Asset Productivity Ratio
+312% / +242%In 3 years sales changed by +312% while total assets changed by +242%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-6.2×Operating cash was negative last year, while some debt falls due within a year.
Higher than 57% of Healthcare companies in United States.
Cash Cushion Ratio
+65%Cash, after subtracting all debt, equals 65% of its market value (net cash).
Higher than 82% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Abeona Therapeutics Inc. made a loss over the last year. Abeona Therapeutics Inc. owes $0.29 for every $1 it owns. Abeona Therapeutics Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossAbeona Therapeutics Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.96The share price is 1.96 times Abeona Therapeutics Inc.'s book value per share, lower than 59% of Healthcare companies in United States.
Market cap
$252 MThe total market value of all of Abeona Therapeutics Inc.'s shares at today's price (share price × number of shares), smaller than 54% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$128 MWhat Abeona Therapeutics Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$2.24Net worth divided by the number of shares. The share price of $4.40 is 2.0 times this, which is the P/B above.
Return on equity (ROE)
-43.1%Abeona Therapeutics Inc. lost 43.1% of its shareholders' money over the last year, higher than 53% of Healthcare companies in United States.
Owes vs Owns
0.29×Abeona Therapeutics Inc. owes $0.29 for every $1 it owns (low), lower than 61% of Healthcare companies in United States.
Dividend yield
NoneAbeona Therapeutics Inc. does not currently pay a dividend.
Profit growth
Back to profitAbeona Therapeutics Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Profit margin
1223.1%Abeona Therapeutics Inc. keeps $1223 of every $100 of revenue as net profit.
Cash quality
-1.1×Cash from Abeona Therapeutics Inc.'s business was -1.1× its reported profit in the year to Dec 2025 — the business used cash even though it reported a profit.
Interest cover
Not coveredAbeona Therapeutics Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashAbeona Therapeutics Inc. held $166 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Abeona Therapeutics Inc.: $252 M ÷ $128 M (30 Jun 2026) = 2.0.
What is Abeona Therapeutics Inc.'s return on equity?
Abeona Therapeutics Inc. lost 43.1% of its shareholders' money over the last year, higher than 53% of Healthcare companies in United States.
How much does Abeona Therapeutics Inc. owe compared with what it owns?
Abeona Therapeutics Inc. owes $0.29 for every $1 it owns (low), lower than 61% of Healthcare companies in United States.
Does Abeona Therapeutics Inc. pay a dividend?
No. Abeona Therapeutics Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.